Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$71.71 USD
+0.19 (0.27%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $71.76 +0.05 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Earnings News For AXSM
-
Why Is Axsome (AXSM) Down 4% Since Last Earnings Report?
-
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
-
Axsome: Q4 Earnings Snapshot
-
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
-
Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Why Is Axsome (AXSM) Up 8.7% Since Last Earnings Report?
-
Axsome (AXSM) Q3 Loss Widens, Revenues Surpass Estimates
-
Axsome: Q3 Earnings Snapshot
-
Axsome Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
-
Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
-
Why Is Axsome (AXSM) Up 8.6% Since Last Earnings Report?
-
Axsome (AXSM) Q2 Earnings Beat, Stock Dips on Pipeline Updates
-
Axsome Therapeutics (AXSM) Reports Q2 Loss, Tops Revenue Estimates
-
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
-
Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?
-
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises
-
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
-
Axsome: Q1 Earnings Snapshot
-
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
-
Axsome (AXSM) Down 9.8% Since Last Earnings Report: Can It Rebound?
-
Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales
-
Axsome: Q4 Earnings Snapshot
-
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
-
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update